JCR Pharmaceuticals Co., Ltd.
Simbols: JCRRF
PNK
6.2
USDTirgus cena šodien
18.8882
P/E koeficients
-0.0016
PEG koeficients
773.77M
MRK Cap
- 0.00%
DIV ienesīgums
JCR Pharmaceuticals Co., Ltd. (JCRRF) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 13278 | 30977 | 26260 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | -214 | 244 | -225 | |||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 11137 | 15585 | 8183 | |||||||||||||||||||
balance-sheet.row.inventory | 0 | 18514 | 14636 | 13554 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 4873 | 990 | 548 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 47802 | 62188 | 48545 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 32681 | 26782 | 17172 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 3652 | 2960 | 3232 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3652 | 2960 | 3232 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 9081 | 1986 | 2797 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 1357 | 2433 | 1739 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 362 | 783 | 296 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 47133 | 34944 | 25236 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 2 | 3 | |||||||||||||||||||
balance-sheet.row.total-assets | 0 | 94937 | 97134 | 73784 | |||||||||||||||||||
balance-sheet.row.account-payables | 0 | 1563 | 1324 | 2932 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 17300 | 15150 | 12850 | |||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33 | 5915 | 2646 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5500 | 2950 | 5250 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | -428 | -343 | -378 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 12975 | 13472 | 9687 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 6763 | 3994 | 6203 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 73 | 44 | 42 | |||||||||||||||||||
balance-sheet.row.total-liab | 0 | 42525 | 46048 | 35231 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 0 | 9061 | 9061 | 9061 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 34273 | 33241 | 20904 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1421 | 1184 | 1159 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 7406 | 7395 | 7255 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 52161 | 50881 | 38379 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 94937 | 97134 | 73784 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 251 | 205 | 174 | |||||||||||||||||||
balance-sheet.row.total-equity | 0 | 52412 | 51086 | 38553 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||||
Total Investments | 0 | 8867 | 2230 | 2572 | |||||||||||||||||||
balance-sheet.row.total-debt | 0 | 22800 | 18100 | 18100 | |||||||||||||||||||
balance-sheet.row.net-debt | 0 | 9522 | -12633 | -8160 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 5412 | 19404 | 8653 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1997 | 1945 | 1892 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -9221 | -3074 | -983 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 173 | 177 | 149 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -2956 | -9030 | 323 | |||||||||||||||||||
cash-flows.row.account-receivables | 0 | 3269 | -7501 | -204 | |||||||||||||||||||
cash-flows.row.inventory | 0 | -3877 | -1082 | -4699 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 238 | -1608 | 2253 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2586 | 1161 | 2973 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -905 | -133 | 307 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8560 | -11333 | -7527 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6717 | 8167 | -2747 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -906 | -300 | -391 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 259 | 300 | 584 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 922 | -84 | 6791 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -15002 | -3250 | -3290 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -3050 | -750 | -650 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 10 | 10 | 13 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -10 | -10 | -13 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -2739 | -2169 | -1083 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 7737 | 740 | 10037 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1948 | -2179 | 8304 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1099 | 612 | -22 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -17455 | 4473 | 15332 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 13278 | 30733 | 26260 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 30733 | 26260 | 10928 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -5500 | 9289 | 10341 | |||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -8560 | -11333 | -7527 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -14060 | -2044 | 2814 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 34343 | 51082 | 30085 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 8886 | 10461 | 7812 | |||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 25457 | 40621 | 22273 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 58 | 38 | 61 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 20480 | 20686 | 14003 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 29366 | 31147 | 21815 | |||||||||||||||||||
income-statement-row.row.interest-income | 0 | 33 | 7 | 7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 44 | 45 | 42 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 437 | -529 | 384 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 58 | 38 | 61 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 437 | -529 | 384 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 44 | 45 | 42 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1997 | 1945 | 1892 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 0 | 4975 | 19933 | 8269 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 5412 | 19404 | 8653 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 1625 | 4886 | 1764 | |||||||||||||||||||
income-statement-row.row.net-income | 0 | 3772 | 14507 | 6892 |
Biežāk uzdotie jautājumi
Kas ir JCR Pharmaceuticals Co., Ltd. (JCRRF) kopējie aktīvi?
JCR Pharmaceuticals Co., Ltd. (JCRRF) kopējie aktīvi ir 94937000000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.748.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 45.128.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.130.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.189.
Kāda ir JCR Pharmaceuticals Co., Ltd. (JCRRF) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 3772000000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 22800000000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 20480000000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.